CDEX RECEIVES NEW PATENT AWARD
New PR on patent award:
U. S. Patent and Trademark Office Issues Patent to CDEX Inc.
Wednesday December 27, 10:00 am ET
Provides System and Methods for Detection and Identification of Chemical Substances
ROCKVILLE, Md.--(BUSINESS WIRE)--CDEX Inc. (OTCBB:CEXI - News) announced today that the US Patent and Trademark Office (USPTO) has issued patent number 7,154,102 to CDEX Inc. The patent relates to system and method for detection and identification of chemical substances.
ADVERTISEMENT
Patent Abstract
The invention provides a system and method utilizing, among other things, fluorescence spectroscopy in the ultra-violet portion of the electromagnetic spectrum to determine chemical species and concentrations. The basic measuring system includes optics, a spectrograph, a detector, and an energy source ("head" components), along with a computer and control electronics and power source capable of generating and detecting unique fluorescence signatures for individual and unique mixtures of chemical substances including, for example, prescribed and/or compounded medications, alcohol products, food types, synthetic drugs, narcotics, perfumes, liquids, and the like.
"The issuance of this patent is a major milestone achievement for CDEX and affirms both our core technology and our approaches to applying it to a system and method that can be used to detect and identify chemical substances across multiple applications and settings," said Jim Griffin, CEO of CDEX Inc. "It will strengthen our ValiMed product offering and allow us to create future value for the company by applying this patent to the development of life safety products for the healthcare, security, and brand protection markets."
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements. |
